These agents target meningioma pathological relevant molecules and signaling pathways, including RTKs, Raf, PI3K, mTOR, MEK, WNT/β-catenin, and Hedgehog/Smoothened (Supplementary Table S3). The gene discussed is MTOR; the disease is meningioma.